A5026216199- Glioma Diagnosis and Treatment
- Nanoplatforms for cancer theranostics
- Cancer, Hypoxia, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Advanced MRI Techniques and Applications
- MRI in cancer diagnosis
- Protein Degradation and Inhibitors
- Click Chemistry and Applications
- Chemical Synthesis and Analysis
- Cancer Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Barrier Structure and Function Studies
- Privacy-Preserving Technologies in Data
- Immune cells in cancer
- Ultrasound and Hyperthermia Applications
- Mitochondrial Function and Pathology
- Advanced biosensing and bioanalysis techniques
- RNA Interference and Gene Delivery
- Nanoparticle-Based Drug Delivery
- Drug Transport and Resistance Mechanisms
- Obesity, Physical Activity, Diet
- Microtubule and mitosis dynamics
Luxembourg Institute of Health
2015-2024
Stanford University
2021-2023
University of Bergen
2011-2016
Laboratoire National de Santé
2011-2014
Umeå University
2013
Bevacizumab, an antibody against vascular endothelial growth factor (VEGF), is a promising, yet controversial, drug in human glioblastoma treatment (GBM). Its effects on tumor burden, recurrence, and physiology are unclear. We therefore determined the response to bevacizumab at phenotypic, physiological, molecular level clinically relevant intracranial GBM xenograft model derived from patient spheroids. Using anatomical physiological magnetic resonance imaging (MRI), we show that causes...
Angiogenesis is regarded as a hallmark of cancer progression and it has been postulated that solid tumor growth depends on angiogenesis. At present, however, clear cell invasion can occur without angiogenesis, phenomenon particularly evident by the infiltrative malignant brain tumors, such glioblastomas (GBMs). In these amplification or overexpression wild-type (wt) truncated constitutively activated epidermal factor receptor (EGFR) are important events in GBM development, where complex...
Anti-angiogenic therapy in glioblastoma (GBM) has unfortunately not led to the anticipated improvement patient prognosis. We here describe how human GBM adapts bevacizumab treatment at metabolic level. By performing (13)C6-glucose flux analysis, we show for first time that tumors undergo re-programming toward anaerobic metabolism, thereby uncoupling glycolysis from oxidative phosphorylation. Following treatment, an increased influx of was observed into tumors, concomitant lactate levels and...
Research Article20 October 2017Open Access Transparent process Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways Fred Fack NorLux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute Health, City, Search for more papers by this author Saverio Tardito Cancer Metabolism Unit, UK, Beatson Institute, Glasgow, UK Guillaume Hochart IMABIOTECH, Loos, France Anais Oudin Liang Zheng Sabrina Fritah Anna Golebiewska Petr V...
Patient-based cancer models are essential tools for studying tumor biology and the assessment of drug responses in a translational context. We report establishment large cohort unique organoids patient-derived orthotopic xenografts (PDOX) various glioma subtypes, including gliomas with mutations IDH1, paired longitudinal PDOX from primary recurrent tumors same patient. show that PDOXs enable long-term propagation patient represent clinically relevant avatars retain histopathological,...
Amplification of the epidermal growth factor receptor (EGFR) and its mutant EGFRvIII are among most common genetic alterations in glioblastoma (GBM), frequent aggressive primary brain tumor.In present work, we analyzed clonal evolution these major EGFR aberrations a small cohort GBM patients using unique surgical multisampling technique. Furthermore, overexpressed both receptors separately together 2 patient-derived stem cell lines (GSCs) to analyze their functions vivo orthotopic xenograft...
The histopathological and molecular heterogeneity of glioblastomas represents a major obstacle for effective therapies. Glioblastomas do not develop autonomously, but evolve in unique environment that adapts to the growing tumour mass contributes malignancy these neoplasms. Here, we show patient-derived glioblastoma xenografts generated mouse brain from organotypic spheroids reproducibly give rise three different histological phenotypes: (i) highly invasive phenotype with an apparent normal...
Deregulated growth factor signaling is a major driving force in the initiation and progression of glioblastoma. The tumor suppressor stem cell marker Lrig1 negative regulator epidermal receptor (EGFR) family. Here, we addressed therapeutic potential soluble form (sLrig1) glioblastoma treatment mechanism sLrig1-induced inhibition. With use encapsulated cells, recombinant sLrig1 was locally delivered orthotopic xenografts generated from freshly isolated patient tumors. Tumor mouse survival...
Glioblastoma (GBM) is a typically lethal type of brain tumor with median survival 15 months postdiagnosis. This negative prognosis prompted the exploration alternative treatment options. In particular, reliance GBM on angiogenesis triggered development anti-VEGF (vascular endothelial growth factor) blocking antibodies such as bevacizumab. Although its application in human only increased progression-free periods but did not improve overall survival, physicians and researchers still utilize...
Abstract Early-life adversity covers a range of physical, social and environmental stressors. Acute viral infections in early life are major source such have been associated with broad spectrum later-life effects outside the immune system or “off-target”. These include an altered hypothalamus–pituitary–adrenal (HPA) axis metabolic reactions. Here, we used murine post-natal day 14 (PND 14) Influenza A (H1N1) infection model applied semi-holistic approach including phenotypic measurements,...
Tumor organoids and patient-derived orthotopic xenografts (PDOXs) are some of the most valuable pre-clinical tools in cancer research. In this protocol, we describe efficient derivation PDOX models from glioma patient tumors. We provide detailed steps for organoid culture, intracranial implantation, detection tumors brain. further present technical adjustments standardized functional assays drug testing. For complete details on use execution please refer to Golebiewska et al. (2020).
Childhood obesity is associated with early cardiometabolic risk (CMR), increased of adulthood obesity, and worse health outcomes. Leg fat mass (LFM) protective beyond total (TFM) in adults. However, the limited evidence children remains controversial.We investigated relationship between LFM CMR factors youth.A 203 overweight/obese children, 7-17-yr-old, followed Pediatric Clinic, Luxembourg.TFM by dual energy x-ray absorptiometry a detailed set markers were analyzed.After TFM, age, sex, body...
Patients with melanoma have a high risk of developing brain metastasis, which is associated dismal prognosis. During early stages metastasis development, the blood-brain barrier (BBB) likely intact, inhibits sufficient drug delivery into metastatic lesions. We investigated ability peptide, K16ApoE, to permeabilize BBB for improved treatment targeted therapies preclinically. Dynamic contrast enhanced MRI (DCE-MRI) was carried out on NOD/SCID mice study therapeutic window peptide-mediated...
Neo-angiogenesis represents an important factor for the delivery of oxygen and nutrients to a growing tumour, is considered be one main pathodiagnostic features glioblastomas (GBM). Anti-angiogenic therapy by vascular endothelial growth (VEGF) blocking agents has been shown lead morphological normalisation resulting in reduction contrast enhancement as seen magnetic resonance imaging (MRI). Yet functional consequences this its potential improved cytotoxic tumour are not known. The presented...
Epigenetic modifications play a major role in the development of multiple myeloma. We have previously reported that PPARγ agonist pioglitazone (PIO) enhances, in-vitro, cytotoxic effect Histone deacetylase inhibitor (HDACi), valproic acid (VPA), on myeloma cells. Here, we described new mouse model using MOLP8 cells, order to evaluate VPA/PIO combination progression by analyzing proliferation bone marrow plasma showed delays disease and invasion cells marrow. Mechanistically, demonstrated...
Anti-programmed death 1 (PD-1) is a revolutionary treatment for many cancers. The response to anti-PD-1 relies on several properties of tumor and immune cells, including the expression PD-L1 PD-1. Despite impressive clinical benefit achieved with in cancers adults, use this therapy high-risk neuroblastoma remains modest. Here, we evaluated therapeutic combination JQ1 highly relevant TH-MYCN transgenic mouse model. small molecule inhibitor extra-terminal domain (BET) family bromodomain...
This research paper presents a novel approach to the prediction of hypoxia in brain tumors, using multi-parametric Magnetic Resonance Imaging (MRI). Hypoxia, condition characterized by low oxygen levels, is common feature malignant tumors associated with poor prognosis. Fluoromisonidazole Positron Emission Tomography (FMISO PET) well-established method for detecting vivo, but it expensive and not widely available. Our study proposes use MRI, more accessible cost-effective imaging modality,...
Background The efficiency of traditional anthropometric measurements such as body mass index (BMI) or waist circumference (Waist C) used to replace biomedical imaging for assessing visceral adipose tissue (VAT) is still highly controversial in youth. Hypothesis and Objectives We evaluated the most accurate model predicting VAT overweight/obese youth, using various their correlation with different fat compartments, especially by testing, first time hypothesis that subtracting measurement...